Sign inCreate account

Report workspace tools

NCT07466017RECRUITINGanonymous

A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of CS060380 Tablets in Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH) and Obesity.

Sponsor

Source record

Cascade Pharmaceuticals, Inc

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

CS060380 is a THR-beta agonist targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity.

Indication / condition

AI-normalized

Metabolic Dysfunction-associated Steatohepatitis (MASH)

Intervention

Source record

semaglutide, CS060380, Placebo

Source & freshness

Source record

NCT ID

NCT07466017

Original source

ClinicalTrials.gov

Source last updated

May 20, 2026

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07466017

Title

A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of CS060380 Tablets in Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH) and Obesity.

Sponsor

Cascade Pharmaceuticals, Inc

Status

RECRUITING

Phase

Phase 2

Condition raw

Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity

Condition normalized

Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity

Modality raw

small molecule

Modality normalized

small molecule

Target raw

CS060380 is a THR-beta agonist targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity.

Target normalized

CS060380 is a THR-beta agonist targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity.

Interventions

semaglutide, CS060380, Placebo

Public preview

Source record

Cascade Pharmaceuticals, Inc. is advancing CS060380 in a Phase II trial to evaluate its efficacy and safety in combination with semaglutide for treating MASH and obesity. The market for obesity and related liver diseases is significant, with increasing prevalence globally. The combination therapy approach may provide a competitive edge against existing treatments, particularly as semaglutide has shown promise in weight management. Successful trial outcomes could position Cascade favorably in a growing market, but diligence is required regarding regulatory pathways and potential competition from other obesity and liver disease therapies.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of CS060380 Tablets in Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH) and Obesity.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT07466017

Status

RECRUITING

Phase

Phase 2

Sponsor

Cascade Pharmaceuticals, Inc

Executive brief

Investment-Ready Snapshot

Cascade Pharmaceuticals, Inc. is advancing CS060380 in a Phase II trial to evaluate its efficacy and safety in combination with semaglutide for treating MASH and obesity. The market for obesity and related liver diseases is significant, with increasing prevalence globally. The combination therapy approach may provide a competitive edge against existing treatments, particularly as semaglutide has shown promise in weight management. Successful trial outcomes could position Cascade favorably in a growing market, but diligence is required regarding regulatory pathways and potential competition from other obesity and liver disease therapies.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 20, 2026
Internal syncJun 09, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07466017

Indication

Metabolic Dysfunction-associated Steatohepatitis (MASH)

Modality

small molecule

Target

CS060380 is a THR-beta agonist targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity.

Intervention

semaglutide, CS060380, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.